PDF format only. Topics: Defibrillators

continue reading.....

Children born with hydrocephalus, or “water on the brain” must have shunts implanted to drain the fluid away from the brain to reduce harmful pressure.

continue reading.....

In a proposal to the Federal Government, the Pharmacy Guild of Australia is recommending that pharmacists should be allowed to write repeat scripts for chronic conditions for up to 12 months as well as writing repeat scripts for low dose statins, the contraceptive pill and certain antibiotics, saying this will free up doctors’ time.

continue reading.....

Doctors must maintain sole responsibility for prescribing medication to patients, AMA (Australian Medical Association) President, Dr Rosanna Capolingua said today. “No medication is without risk,” Dr Capolingua said. “The right medication and the right dose at the right time for the patient is essential. Patients do not want to take unnecessary or inappropriate medication, and they want to be sure that what they are taking is right for them at the time.

continue reading.....

Talecris Biotherapeutics, Inc. announced today that the European Commission followed an opinion of the Committee for Orphan Medicinal Products (COMP) and has granted orphan drug designation to Talecris’ alpha-1 proteinase inhibitor (human) for inhalation use in the treatment of congenital Alpha1-Antitrypsin Deficiency (also known as AAT Deficiency or Alpha-1). Currently, there are no approved aerosolized treatments available for augmentation therapy for AAT Deficiency.

continue reading.....

The NPA Education and Training Department is now taking bookings for the Preregistration Trainee Pharmacist Training Programme 2008/2009. The programme covers key components of the syllabus as well as those elements that are difficult to cover in the pharmacy (e.g. First Aid Training). Candidates will have a choice of three venues for the study courses: Wakefield, Birmingham and St Albans.

continue reading.....

The NPA has produced a new standard operating procedure (SOP) for the supply of opioid medicines. The document provides details of the National Patient Safety Agency (NPSA) rapid response report: Reducing Dosing Errors with Opioid Medicines. Further information resources about opioid medicines and a standard template SOP which members can modify to correspond with their own pharmacy, are also included in the document.

continue reading.....

Genentech Forms Special Committee of Independent Directors to Review Roche Proposal Genentech, Inc. (NYSE:DNA) announced today that it has formed a special committee of its Board of Directors, composed of the company’s three independent directors, to assess the proposal from Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $89.00 in cash per share. The special committee members are Herbert W. Boyer, Ph.D., Debra L. Reed and Charles A.

continue reading.....